博晖创新(300318.SZ)：控股子公司人凝血因子Ⅷ获得药品注册证书

Core Viewpoint - The company BoHui Innovation (300318.SZ) has received approval from the National Medical Products Administration for its drug, Human Coagulation Factor VIII, which is intended to treat bleeding symptoms in patients with Hemophilia A and acquired Factor VIII deficiency [1] Group 1 - BoHui Bio-Pharmaceutical (Hebei) Co., Ltd., a subsidiary of BoHui Innovation, developed the Human Coagulation Factor VIII [1] - The drug is designed to correct coagulation dysfunction caused by a deficiency of Human Coagulation Factor VIII [1] - The primary applications of the drug include the prevention and treatment of bleeding symptoms in patients with Hemophilia A and during surgical procedures for these patients [1]